Black Diamond Therapeutics

📍 Cambridge, United States🗓 Founded 2017👥 43 employees💰 Last funded 2020
Biotechnology Research🌐 blackdiamondtherapeutics.com
Website LinkedIn
Black Diamond Therapeutics is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations, expanding the addressable patient population by offering one solution for many mutations. Our mission: defeat cancer resistance and provide people living with cancer the opportunity to experience longer, healthier and more active lives. We are advancing two potent, brain-penetrant clinical-stage programs: BDTX-1535, a fourth-generation EGFR inhibitor targeting non-small cell lung cancer (NSCLC) and glioblastoma (GBM) and BDTX-4933, a RAF inhibitor targeting KRAS, NRAS and BRAF alterations in NSCLC and other solid tumors.
5
Total investors
4
Early stage
1
Mid stage
0
Late stage
2017
Founded

Investors

5 investors
All
Early stage
Mid stage
Late stage
Investor geography1 country
United States
2
Investor activity2014–2020 · investors recorded per year
20141201822019120201
Recent (last 2y)Earlier
Frequently asked questions
Who invested in Black Diamond Therapeutics?
Black Diamond Therapeutics has 5 investors on record on gritt.io, including 4 early-stage backers, 1 mid-stage.
When did Black Diamond Therapeutics last raise funding?
The most recent investment in Black Diamond Therapeutics recorded on gritt.io was in 2020.
When was Black Diamond Therapeutics founded?
Black Diamond Therapeutics was founded in 2017.
What industry is Black Diamond Therapeutics in?
Black Diamond Therapeutics operates in Biotechnology Research. Find similar Biotechnology Research investors on gritt.io.
Where is Black Diamond Therapeutics based?
Black Diamond Therapeutics is headquartered in Cambridge, United States.